Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NQO1 | P15559 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL6551886 | 0.92 | KDM4E (0.54) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL891550 | 0.85 | MAOA (0.68) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL21961896 | 0.85 | ELANE (0.56) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL9787769 | 0.79 | MAOA (0.74) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL30205812 | 0.79 | MAOA (0.57) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL339615 | 0.79 | MAOA (0.57) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL304367 | 0.78 | KMT2A (0.62) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL29709713 | 0.78 | KMT2A (0.62) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL29416517 | 0.78 | KMT2A (0.62) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 | |
| SCHEMBL4696277 | 0.77 | MAOA (0.90) | KDM4EALDH1A1MAOACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466765-B | Sodium 8- (2-hydroxybenzoyl) octoate and synthetic method thereof | 成都道合尔医药技术有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117466765-A | Sodium 8- (2-hydroxybenzoyl) octoate and synthetic method thereof | 成都道合尔医药技术有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-5583235-A | ALKENYLATION, CYCLIZATION | SHAMAN PHARMACEUTICALS, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1995024404-A1 | PREPARATION OF SYMMETRICAL AND UNSYMMETRICAL DITHIIN COMPOUNDS | SHAMAN PHARMACEUTICALS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0283775-B1 | Use of capping agents to improve the stability of polyphenylene ether to oxidative degradation. | GEN ELECTRIC (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0283775-A1 | Use of capping agents to improve the stability of polyphenylene ether to oxidative degradation. | GENERAL ELECTRIC COMPANY (US) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | KDM4E 2224/4885ALDH1A1 2233/4885MAOA 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.